We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
Cap. Flow
-$4.15B
Cap. Flow %
-9.34%
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$309M
2
XOM icon
ExxonMobil
XOM
+$302M
3
AMZN icon
Amazon
AMZN
+$291M
4
C icon
Citigroup
C
+$253M
5
SHOP icon
Shopify
SHOP
+$238M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$383M
2
JNJ icon
Johnson & Johnson
JNJ
+$312M
3
JPM icon
JPMorgan Chase
JPM
+$285M
4
T icon
AT&T
T
+$191M
5
DG icon
Dollar General
DG
+$187M

Sector Composition

Rank Sector Weight
1 Healthcare 15.63%
2 Financials 15.61%
3 Technology 14.28%
4 Consumer Discretionary 13.21%
5 Industrials 5.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LCW.WS
1601
CALL
DELISTED
Learn CW Investment Corporation Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
LCW.WS
$2.42M 0.01%
236,667
-56,024
-19% -$3.84K
BAP icon
1602
Credicorp
BAP
$30.9B
$2.4M 0.01%
+17,695
New +$2.51M
LEGAW
1603
CALL
DELISTED
Lead Edge Growth Opportunities, Ltd Warrant
LEGAW
$2.4M 0.01%
237,493
ASCB
1604
DELISTED
A SPAC II Acquisition Corp. Ordinary Shares
ASCB
$2.39M 0.01%
234,115
CHAA.WS
1605
CALL
DELISTED
Catcha Investment Corp Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
CHAA.WS
$2.39M 0.01%
236,816
-129,845
-35% -$3.02K
PTON icon
1606
Peloton Interactive
PTON
$2.84B
$2.38M 0.01%
300,230
+4,830
+2% +$46.3K
TVGN icon
1607
Tevogen Bio Holdings
TVGN
$23.6M
$2.38M 0.01%
4,611
-7,487
-62% -$3.83M
CITEW
1608
CALL
DELISTED
Cartica Acquisition Corp Warrant
CITEW
$2.37M 0.01%
227,414
RY icon
1609
Royal Bank of Canada
RY
$295B
$2.36M 0.01%
25,130
+12,330
+96% +$1.16M
FA icon
1610
First Advantage
FA
$3.58B
$2.36M 0.01%
181,611
-340,446
-65% -$4.45M
IOVA icon
1611
Iovance Biotherapeutics
IOVA
$2.1B
$2.36M 0.01%
+369,463
New +$2.88M
IMO icon
1612
Imperial Oil
IMO
$60.8B
$2.35M 0.01%
+48,257
New +$2.49M
HLT icon
1613
Hilton Worldwide
HLT
$73.4B
$2.35M 0.01%
18,576
-370,580
-95% -$48.8M
AOS icon
1614
A.O. Smith
AOS
$8.82B
$2.35M 0.01%
41,007
+34,207
+503% +$1.91M
JILL icon
1615
J. Jill
JILL
$278M
$2.34M 0.01%
94,435
+37,167
+65% +$821K
KO icon
1616
CALL
Coca-Cola
KO
$380B
$2.33M 0.01%
+36,700
New +$2.22M
APEI icon
1617
American Public Education
APEI
$917M
$2.33M 0.01%
189,547
-38,941
-17% -$483K
EVRI
1618
DELISTED
Everi Holdings
EVRI
$2.32M 0.01%
161,779
+91,513
+130% +$1.52M
IMMR icon
1619
Immersion
IMMR
$254M
$2.31M 0.01%
+329,088
New +$2.12M
TXT icon
1620
Textron
TXT
$15.6B
$2.31M 0.01%
32,605
-40,373
-55% -$2.74M
CATO icon
1621
Cato Corp
CATO
$67.3M
$2.3M 0.01%
246,958
+210,760
+582% +$2.16M
MAGN
1622
Magnera Corp
MAGN
$498M
$2.3M 0.01%
63,711
+40,946
+180% +$1.67M
EVH icon
1623
Evolent Health
EVH
$421M
$2.3M 0.01%
81,950
-281,790
-77% -$8.08M
PRFT
1624
DELISTED
Perficient Inc
PRFT
$2.3M 0.01%
32,938
-31,560
-49% -$2.18M
UTAAW
1625
CALL
DELISTED
UTA Acquisition Corporation Warrants
UTAAW
$2.3M 0.01%
224,999

Similar funds

Marshall Wace's Q4 2022 Portfolio in Review

As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.

Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.

Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.

  • Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
  • Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
  • Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
  • Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
  • Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
  • Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
  • Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.